[Frontiers in Bioscience 18, 504-519, January 1, 2013]

TGM2 and implications for human disease: role of alternative splicing

Thung-S. Lai1, 2, Charles S. Greenberg1

1Department of Medicine, Medical University of South Carolina, Charleston, SC 29425. USA, 2Institute of Biomedical Science, Mackay Medical college, New Taipei city, Taiwan, ROC


1. Abstract
2. Introduction
3. Biochemistry of TGM2
3.1. Transamidation Reaction (TGase)
3.2. Regulation of TGase
3.3. G protein and Kinase.
4. Structure and Function of TGM2
4.1. TGase active site
4.2. GTP and ATP binding site
5. Biology of TGM2
6. Alternative Splicing Forms of TGM2
6.1. Importance of C-terminal residues of TGM2
6.2. tTGH and tTGH2
6.3. tTGV1 and tTGV2
7. Impact of alternative splicing of TGM2 in various diseases and biology
7.1. Epithelial-Mesenchymal Transition (EMT)
7.2. Autoimmunity
7.3. Neurodegenerative diseases
7.3.1. Huntington's disease
7.3.2. Parkinson's disease (PD)
7.3.3. Alzheimers' disease (AD)
7.4. Inflammatory Diseases
7.5. Wound healing and fibrosis
7.6. Cell Adhesion
8. Acknowledgement
9. References


Alternative splicing is an important mechanism for modulating gene function that accounts for a considerable proportion of proteomic complexity in higher eukaryotes. Alternative splicing is often tightly regulated in a cell-type- or developmental-stage- specific manner and can cause a single gene to have multiple functions. Human Tissue transglutaminase (TGM2) is a multifunctional enzyme with transglutaminase crosslinking (TGase), G protein signaling and kinase activities that are postulated to play a role in many disease states. TGM2 mRNA is regulated by alternative splicing, producing C-terminal truncated forms of TGM2 that are predicted to have distinct biochemical properties and biological functions. In this review, we will discuss how alternatively spliced forms of TGM2 could modulate its roles in cancer, neurodegeneration, inflammation and wound healing.


Tissue transglutaminase (TGM2) is perhaps one of the best examples of the functional diversity of a single gene product. Known as a thiol- and Ca+2-dependent transglutaminase enzyme (TGase)(1-3), TGM2 was later found to receive signals from G-protein coupled receptors (GPCRs) including a1b-adrenergic (aAR), oxytocin and thromboxane receptors (4, 5). It has also been reported to have a kinase function that can transmit cell membrane signals (6-8). This is an example of how a single molecule can function in a unique manner depending upon its location in the extracellular matrix, cell surface, cytoplasm or nucleus (2, 9). Early biochemical data demonstrated that TGM2 could bind and hydrolyze GTP and ATP (10-13). In addition, TGM2 also functioned as an adhesion molecule involved in an integrin-mediated signaling event (14-16). Recently, TGM2 was reported to display protein disulphide isomerase activity (PDI) (17); an activity involved in the formation and breakage of disulfide bonds between cysteine residues. Alterations in TGM2 activity and function have been linked to cancer, inflammatory diseases (atherosclerosis), neurodegeneration, tissue fibrosis, autoimmunity, and celiac disease (2, 3, 9). In cancer, over-expression of TGM2 was found to promote cell survival and chemotherapy resistance of the tumor cells (18-20). TGM2 knock out studies in cancer cell lines established that TGM2 expression was associated with cell migration, metastasis, epidermal growth factor (EGF) signaling/cell migration and epithelial to mesenchymal transition (20-22). Since there are four alternatively spliced forms of TGM2, it remains unknown whether full length TGM2 or spliced isoforms can participate in these cellular events. There may be unique structure-function relationships of these isoforms that could play a role in disease processes In the following section, details regarding function of TGM2 isoforms and their regulation will be discussed.


3.1. Transamidation reaction (TGase)

TGM2 belongs to a family of closely related thiol enzymes known as transglutaminases (TGs) that are derived from a common ancestral gene (2, 3, 9). At least eight enzymatically active TGs have been identified (2). TGM2 catalyzes a crosslinking reaction between a specific g-glutamyl (Q) containing peptide substrate and either a e-amine group from a peptide-bound Lys (K) residue or a free primary amine (Figure 1). These reactions result in post-translational modifications of proteins that can alter their solubility, structure and function. When a peptide-bound K residue serves as the acyl-acceptor of the reaction, the formation of g-glutamyl-e-lysine (isopeptide) bonds results in the formation of either inter- or intra-isopeptide bond (Figure 1a). Many intra- and extracellular proteins have been identified as TGM-2 substrates (2). To date, there are at least 150 substrates reported on TRANSDAB database (http://genomics.dote.hu/wiki/index.php/Category:Tissue_transglutaminase). The intracellular substrates that are often cited include K rich nuclear core histones, huntingtin, NFkB, inhibitor alpha and glyceraldehyde-3-phosphate dehydrogenase (G3PDH) (23-28). Extracellular crosslinking is important in extracellular matrix (ECM) production and stabilization (3, 29). There are a number of extracellular matrix (ECM) substrates including fibronectin (FN), collagens, osteopontin, nidogen/entactin, vitronectin and osteonectin (3, 29).

When a peptide-bound K residue is not available, the reaction with amines/polyamines results in the incorporation of the primary amino group and the formation of a g-glutamyl-amine/polyamine bond (Figure 1b; polyamination)(2). Biogenic primary amines, such as putrescine, spermine, spermidine, serotonin and histamine, are potential primary amine substrates of TGase (2, 3). At low pH and when a peptide-bound K-residue and amine are not available, water acts as the acyl-acceptor and the resultant hydrolysis reaction yields a glutamic acid (E) residue (deamidation)(Figure 1c)(2, 30). In celiac disease patients, deamidation is a very specific reaction as glutamine residue in the gluten peptide is deamidated and patients develop antibody against TGM2 serving as a diagnostic marker for this disease (2). In addition, hsp20 was recently shown to be deamidated at a specific glutamine residue while distinct glutamines were substrates in other types of crosslinking reactions (31).

3.2. Regulation of TGase

TGase activity is inhibited by GTP, which can be reversed by Ca+2 (10, 32). Under normal conditions, intracellular free Ca+2 (~ 10-7 M) and GTP (~ 100-150 mM) are sufficient to keep the TGase in a latent state to prevent cross-linking of proteins with critical function (2, 10). The activation of intracellular TGase activity is a tightly controlled but poorly understood process that can be beneficial or detrimental to cells. Because of high levels of calcium ions (~mM) in the extracellular space, it is generally believed that TGase is constitutively active (2, 3, 9). However, it was recently reported that TGase is not active due to oxidation and the formation of an intra- chain disulfide bond that is activated by thioredoxin (33, 34). Therefore, the activation of extracellular TGase is also controlled by the redox potential of the environment and availability of thioredoxin. S-nitrosylation of TGM2 was found to inhibit its TGase activity (35, 36). TGM2 was found S-nitrosylated in a young aorta but not in an aged aorta indicating there were more TGase activity in aged aorta (35).

Intracellular TGM2 crosslinking events promote inflammation either by activating the NFkB pathway (27, 37) or minimizing inflammation of apoptotic bodies by promoting their clearance (38). In neurodegenerative diseases, crosslinking of proteins can result in the formation of soluble, neurotoxic, oligomeric aggregates and/or insoluble inclusions depending on the type of crosslinking reaction 39-41). The disease-causing proteins that have been shown as substrates include tau protein, α-synuclein, and huntingtin (39-41).

3.3. G protein and kinase functions

In the presence of Mg+2, TGM2 hydrolyzes GTP to GDP, and functions as a G protein (Gah) which can control b-adrenergic-receptor-mediated signaling transduction pathways that lead to PLCd1 activation (2, 4, 42). PLCd1 activation results in an increase in intracellular calcium which activates the transamidation reaction (2). GTP induces a conformational change that inhibits TGase function by narrowing the active site pocket, this process can be reversed by Ca+2 (10, 32, 43, 44). In contrast to GTP, Mg-ATP binding does not inhibit TGase function but displays kinase activity that phosphorylates histones, retinoblastoma (RB), and P53 (6-8, 10). Kinetic and photoaffinity labeling studies indicated that there are distinct binding sites with the possibility of some common binding residues to both nucleotides (10, 13).

TGM2 binds and phorphorylates insulin growth factor binding protein 3 (IGFBP3) and forms a complex with other proteins with signaling function including ROCK2, glutamate receptor, and GPR44 (6). The peptide fragment associated with IGFBP3 belongs to the N-terminal fragment (AA # 1 to AA 562) of TGM2 (6). Interestingly, TGM2 interacts with protein kinase A and is phosphorylated at Ser216 by protein kinase A (PKA)(45). The phosphorylated-TGM2 creates 14-3-3 binding sites and reduces its TGase activity (45, 46). 14-3-3 protein is an important protein controlling cell cycle progression, metabolism, and apoptosis (47). Silencing TGM2 leads to impaired adhesion and motility of cancer cells by decreasing phosphorylation of AKT kinase (48). It is unknown whether alternatively spliced forms of TGM2 function as G-protein or play a role in cell signaling function.


4.1. TGase active site

X-ray crystallography reveals that TGM2 is composed of an N-terminal b-sandwich (domain I; AA #1-139), a a/b catalytic core (domain II; AA # 140-454), a b-barrel 1 (Domain III; AA # 479-585) and a b-barrel 2 (Domain IV; residue # 586-687)(43, 44) (Figure 2). The TGase active site is composed of a catalytic triad of C277-H335-D358 (43), and the rate-limiting step in catalysis involves the formation of a transitional thioester bond between C277 and the Q substrate (Figure 2).

4.2. GTP and ATP binding site

Based on the 3-D structure of GDP-bound TGM2 (pdb: 1kv3), GTP binding involves the amino acid side chains from domains II, III and IV binding to hydrophobic guanine binding pocket (K173, F174, S482, Met483, L582, Y583), a, b-phosphates (R478, V479, R580, Y583), and g-phosphate (K173 and R476) (43). 3-D structure of ATP-bound TGM2 also demonstrates that ATP and GDP bind to the same nucleotide binding pocket (49). However, S482 and R580 were found to be involved only in guanine, not adenine binding (49). Mutation at R580 to adenine resulted in almost complete loss of GTP/GDP activity but remained active in TGase function (50) and GTP hydrolysis (unpublished observation). Based on biochemical data, GTP hydrolysis domain is localized to the first 47 AAs of domain II (AA #139-186)(13).


TGM2 expression is considered ubiquitous, but the distribution and expression levels vary significantly among different cell types. The highest expression level is found in endothelial cells (ECs) and vascular smooth muscle cells (VSMC) (2, 51). TGM2 is localized at the cell-surface, sub-membrane-associated, cytoplasm, and nucleus of the cell (2). In human neuroblastoma cells, 7% of the total TGM2 that is found in the nucleus is associated with chromatin (52). Retinoic acid (RA) induction causes the redistribution of TGM2 in different subcellular compartments (52). The significance of TGM2 induction associated with intracellular translocation to the nucleus and change in intracellular TGase activity is poorly understood (2, 52). Cell surface TGM2 functions as a cell adhesion molecule and interacts with leukocytes (53), a wide variety of ECM adhesion proteins, including integrins, fibronectin (FN), and GPR56, to increase the adhesive property of cells (14, 54, 55). Membrane-associated TGM2 is reported to interact with GPR56 and IGFBP-3 (insulin growth factor binding protein) kinase in breast cancer cells and is involved in G-protein and ATP kinase signaling function (6, 55). Cytosolic TGM2 was reported to interact with actin (56), glyceraldehyde 3-phosphate dehydrogenase (GAPDH)(25), importin-a3 (57), EIF-5A (58), histones and huntingtin (23).

There are several mechanisms of how TGM2 is localized to the extracellular space. TGM2 binds to FN (2:1 ratio), a glycoprotein present in plasma and the ECM (59), with high affinity (Kd ~8 nM) (60) through its N-terminal b-sandwich domain (Figure 2). FN binding aids in non-classical secretion and localizes TGM2 to the EC surface (54, 61) and the catalytic domain of TGM2 helps stabilize the TGM2-FN interaction (54). Through binding to FN, TGM2 also interacts with b1 and b3 integrins and forms stable ternary complexes (14). A recent study indicates that the secretion of TGM2 utilizes the long loop of endosomal recycling pathway and indicates involvement of endosomal trafficking in non-classical protein secretion (62). TGM2 also binds to heparin sulfate proteoglycans (HSPG) with affinity comparable to FN (63). The binding of TGM2 to HSPG also contributes to its externalization (63, 64). In addition, cancer cells can also utilize microvesicles containing TGM2 and FN to transfer proteins into recipient cells (65).

Increased TGase activity is a common feature of several inflammatory diseases. The TGM2 promoter contains a NFkappaB binding motif (66) and is induced by NFkappaB. Several inflammatory cytokines including IFN-g (67) and TGF-b1 (68) are known to up-regulate TGM2. TGM2 is also involved in the conversion of latent to active TGF-b1 whereas the TGM2 itself is induced by TGF-b1, thus forming a positive feedback loop between the two proteins. TGFb1 expression down regulates inflammatory and autoimmune responses (69).

TGM2 is also induced by RA and inflammatory cytokines (IL-6, TNFa), epidermal growth factor (EGF), and by various stimuli such as UV light, oxidative stress, and viral infection (2, 70). By mechanisms that are currently unknown, TGM2 mediates the expression of the gp91phos subunit of NADPH oxidase expression in PMNs, a gene product that is essential for oxidative killing by generation of superoxide anions (71). These data demonstrate that the induction of the TGM2 is associated with a host response to various stimuli that lead to cell differentiation, inflammation and immune defense.

In earlier studies, we observed co-expression of the TGM2 and active TGF-b1 at sites within wounded regions and at sites of inflammation (72-74). Our group has shown that direct application of recombinant TGM2 to a mammary adenocarcinoma using a dorsal skin flap window chamber model resulted in increased levels of collagen around the tumor, resulting in fibrosis (72). There data demonstrate the role of TGM2 in the wound healing response and abnormal TGM2's activity could lead to tissue fibrosis.


6.1. Importance of C-terminal residues of TGM2

TGM2 mRNA has been reported to be regulated by alternative splicing, producing shorter forms of TGM2 that are predicted to have distinct properties (11, 75-77). There are a total of 4 alternatively spliced forms of human TGM2 in the literature. These include tTGH (also called TGase-S), tTGH2 and tTGV1 and tTGV2 (51, 75, 76) (Figure 3). The roles of different spliced forms of human TGM2 in vivo remain unclear. The difference between TGM2 and its spliced isoforms is their C-terminus. All spliced forms lose their C-terminus to different extents (see the following section for more details). The C-terminus of TGM2 was found to bind to GPCRs including the a1b-adrenergic receptor and an N-terminal adhesion domain of GPR56, a receptor involved in migration and adhesion of tumor cells (78). The C-terminus (AA # 657-664) also contains nuclear export signal peptide sequences that is important for intracellular localization (see below) (79). C-terminus is important for protein stability and GTP/ATP binding (51). Part of the Heparin binding sites are localized at the C-terminal amino acid (AA) # 598-602 (80). In addition, the C-terminus (AA # 661-672) of TGM2 is involved in PLCd1 binding (5). PLCd1 is an isoform of PLC that generates inositol 1,4,5-triphosphate (IP3) and diacyl glycerol, which mobilizes intracellular Ca+2 from the endoplasmic reticulum (ER) (5). The activity of PLCd1 is suppressed by the interaction with TGM2 (42). When GTP binds to TGM2, PLCd1 is released from inhibition (42).

6.2. tTGH and tTGH2

In human erythroleukemia cells, 63 kDa (designated tTGH) and 37-kDa (designated tTGH2) N-terminal fragments of TGM2 were reported (77). tTGH and tTGH2 mRNAs are generated by common alternative splicing events through incorporation of intron X and VI (Intron retention mechanism) (81) and encode proteins with 548 and 349 amino acid residues, respectively (76, 77) (Figure 3). Both mRNAs have alternative polyadenylation site utilization (Figure 3). tTGH, which lacks the C-terminal 138 amino acid residues of TGM2, sometimes referred to as short isoform (S-form, or TGase S) in the literature (82, 83) has been characterized and was found to be up-regulated in brains of Alzheimers' patients. tTGH2 remains uncharacterized. These two forms were not found in human vascular endothelial and smooth muscle cells and may reflect changes derived from leukemogenesis (51).

tTGH is estimated to display < 5% residual TGase activity based on data from the recombinant C-terminal truncation mutant (M1-S538 ) expressed in E. coli (12) (Table 1). The rate of GTP hydrolysis activity of tTGH was found to increase (11, 12), however, it was found to have weak affinity to GTP since the binding was not detectable using photoaffinity labeling (84). A similar observation with high GTP hydrolysis rate (6-7 fold increase) but with low GTP binding was also reported for tTGV1 and tTGV2 (51) (Table 1). It should be noted that low measureable GTP binding does not mean reduced GTP hydrolysis (GTPase) activity. Since TGM2 has high affinity for GTP/GDP as demonstrated by co-purification of GDP and TGM2 in crystal (43), TGM2 is likely to have slow exchange rate for GTP and GDP; i.e., TGM2 has a prolonged "docking time" for the replacement of GDP with a new GTP molecule. Therefore, with weaker GTP binding for tTGH, tTGV1 and tTGV2, they have much higher rates of GTP hydrolysis (51). The significance of high hydrolysis rate of these TGM2 isoforms remains unknown.

6.3. tTGV1 and tTGV2

Two cDNAs encoding additional C-terminal truncated forms, tTGV1 and tTGV2 were identified from human aortic vascular smooth muscle cells (51). tTGV1 and tTGV2 are composed of 674 and 645 amino acid residues that share identical N-terminal 622 amino acids with TGM2 with alternate 52 and 23 amino acids at the C-terminus that translates into proteins with the predicted Mw of 75 and 70 KDa, respectively (Fig 3). tTGV1,2 mRNAs were synthesized by a rare splicing event utilizing alternate splice sites within exons XII and XIII of the TGM2 gene, respectively (Fig 3). Alternative polyadenylation sites are also utilized (Figure 3). The loss of C-terminal 52 AA residues in tTGV1,2 reduces GTP binding, enhances GTP hydrolysis, renders the variants insensitive to GTP inhibition, and results in <10% residual TGase activity (51). The data suggests that C-terminal residues are important in GTP binding and GTP hydrolysis. The reduced affinity for GTP could allow tTGV1,2 to escape regulation by GTP and exhibit TGase activity when there is a transient increase in Ca+2 levels. In addition, the reduced affinity for GTP may allow these isoforms to have higher GTP hydrolysis rate and this could have implications that remain to be determined.

HEK293 cells transfected with vectors expressing tTGV1 and tTGV2 demonstrated a 28- and 5-fold, respectively, reduction in the levels of protein expression demonstrating that the deleted C-terminal 52 AA is important in stabilizing and promoting the half-life of TGM2 (51). This is consistent with the observation that S171E/TGM2, a point mutation GTP binding-deficient mutant, was poorly expressed in NIH3T3 cells (85, 86). Another GTP-deficient mutant, rat R579A/TGM2 (correspond to R580 in human TGM2), also had relatively lower expression levels than wild-type TGM2 in SH-SY5Y cells (87). Its GTP-bound conformation may exclude TGM2 from the intracellular degradation pathway. This also warrants further investigation.

There was unique expression and localization of tTGV1,2 compared with TGM2 in human umbilical vein endothelial cells (HUVECs), vascular smooth muscle cells (VSMC), and leukocytes. In HUVECs, TGM2 mRNA was expressed at 32- and 194-fold higher levels than tTGV1 and tTGV2, respectively, while in HL-60 and leukocytes (MN and PMN cells), the expression of TGM2 is decreased and the difference between TGM2 mRNA and tTGV1 (tTGV2) mRNA are only 2-5-fold difference (51). At the protein level, tTGv1 is either expressed at much higher or similar levels in human leukocytes and HL-60 cells, respectively (51). This could be due to the stability of mRNA or because TGM2 protein is decreased in HL-60 and leukocytes. The abundance of tTGV1,2 and distinct intracellular expression patterns in human vascular cells and leukocytes indicates these isoforms may have unique physiological functions.

In rats, the GTP-independent isoform (s-TGN, also lacking the C-terminal 52 AAs) was isolated upon stimulation with inflammatory cytokines (IL -1b and TNFa) and was induced to high levels in inflammation and in rat brain injury after cerebral and spinal cord injury (88-92). Therefore, the induction and expression of tTGV1/2 and S-TGN could be considered as a response to tissue injury. Similar to tTGV1 and tTGV2, the spliced site of rat S-TGN is also localized at amino acid #622 and generates an alternate 30 amino acids at the C-terminal end. This isoform was shown to be less sensitive to GTP-mediated inhibition of TGase activity (88, 89); however, the TGase activity of rat s-TGN with respect to full-length TGM2 was not reported (88, 89).


TGM2 is involved in many diseases and biological processes (as listed and discussed below). The contribution of these splicing isoforms of TGM2 in these diseases and processes warrants further investigation.

Overall, the loss of C-terminal residues in the splice variants may affect their ability to form complexes with other proteins. Recently, TGM2 secreted in the ECM was found to serve as a ligand for GPR56, an orphan G-protein coupled receptor that is involved in suppressing tumor growth and metastasis (55). The N-terminal domain of GPR56 was found to bind to the C-terminal b-barrels of TGM2 (55). Since the C-terminal b-barrels are required for TGM2 to bind GPR56 (55), tTGH, tTGH2, tTGV1 and tTGV2 may no longer serve as adhesive ligands for GPR56.

The C-terminal AAs (#661-672) of TGM2 are involved in PLCd1 binding (5). The activity of PLCd1 is suppressed by the interaction with TGM2 (42). When GTP binds to TGM2, PLCd1 is released from inhibition (42). PLCd1 shuttles between the cytoplasm and the nucleus (93, 94). By lacking critical C-terminal AAs, tTGV1 and tTGV2 may have a defect in PLCd1 binding and be unable to adopt a GTP-bound conformation, suggesting that PLCd1 function, including its nuclear activity might be enhanced. The interaction of TGM2 with PLCd1 and/or importin-a3 may be an important mechanism that regulates its distribution between the cytosol and nucleus (2, 5, 57). Thus, the potential loss of interaction with PLCd1 may contribute to the unique pattern of intracellular localization of the splice variants.

A putative nuclear localization export signal (NES) was localized at the C-terminus of TGM2 (AA # 657 to 654) (79). Nuclear TGM2 was previously shown to be induced in the nucleus of ethanol or free fatty acids treated hepatic cells. Nuclear TGM2 was shown to crosslink and inactivate the Sp1 transcription factor, leading to caspase-independent hepatic cell death in a tissue culture system. Recently, they showed that ethanol or free fatty acids also induced the accumulation of tTGH in the nucleus, as it lacks the NES. The physiological significance of accumulation of tTGH in the nucleus remains to be determined (79).

The loss of the C-terminus also affects the ability of isoforms to induce cell differentiation (98). TGM2 was unable to induce neuroblastoma cell differentiation, however, over-expression of tTGH (TG2-S in their study) was shown to induce neuroblastome cell differentiation (98). The ability of tTGH to induce neuroblastoma cell differentiation was due to its deficiency in binding to GTP as another GTP binding deficient mutant R580A also showed the same activity.

Recently, the expression of TGM2 and various spliced isoforms has been analyzed using real-time PCR in various normal and cancer cell lines (99). They found in normal cells that the expression of spliced forms are lower and correlated well with the expression of TGM2. However, there is more variability in the relative expression of different isoforms which did not correlate well with the expression of TGM2. Specifically, there was preferential expression of specific TGM2 isoforms (tTGH and tTGH2) from melanoma cell line and prostate cancer biopsies (99). This data is consistent with other reports that alternative splicing is a more active process in cancer cells (100)

7.1. Epithelial-Mesenchymal transition (EMT)

EMT is a critical process in cancer progression (101). EMT is characterized by breakdown of cell junctions and loss of cell polarity, rendering epithelial cells motile and invasive (101). TGM2 positively influences the development of EMT through at least two mechanisms. First, it cross-links the large latent form of TGFb to the extracellular matrix (102), this may concentrate or release bioactive TGFb, an inducer of EMT. TGM2 and TGFb reciprocally induce each other as part of an auto-stimulatory loop, thus emphasizing the role of TGM2 in the EMT process. Second, TGM2 activates NFkB, a recognized EMT inducer, by cross-linking and polymerizing the inhibitor of NFkB, IkBa, leading to its proteasomal degradation (103). Inhibition of TGM2 expression by siRNA blocks EMT induction (19). In addition to affects on TGFb and NFkB (19, 104), TGM2 may affect tumorigenic properties by enhancing integrin binding to ECM components and activating focal adhesion kinase and Src (21). Using breast cancer cell lines as model systems, Kumar et al. suggested TGase activity is not essential for EMT, while GTP binding was important since a over-expression of a GTP binding deficient mutant TGM2/R580A failed to induce EMT phenotype (20). Since R580A/TGM2 is deficient in GTP binding but has enhanced GTP hydrolysis activity (unpublished observation) suggesting it has increased G-protein signaling function, a mutant with no GTP hydrolysis activity will be needed to investigate its role during EMT. All spliced forms (except tTGH2) of TGM2 are deficient in GTP binding and have residual TGase activity, however over-expression of these spliced forms are not postulated to induce EMT.

7.2. Autoimmunity

Intracellularly, TGase activity is important in apoptotic body formation and preventing the release of intracellular proinflammatory substances. Apoptotic bodies also have an anti-inflammatory effect by inducing the anti-inflammation cytokine TGF-b (105). Defects in TGM2 lead to abnormalities in clearing apoptotic cells and cause immune dysfunction and inflammation (106). TGM2-/- mice fail to activate TGFb, have delayed clearance of apoptotic cells and have evidence of autoimmunity (38). All spliced forms have residual TGase activity and over-expression of these spliced forms is postulated to have increased chances of getting autoimmunity.

7.3. Neurodegenerative diseases

TGase-mediated cross-linking is postulated to contribute to several pathologic hallmarks in neurodegenerative diseases including neuroinflammation, accumulation of insoluble protein inclusions, and proteasome dysfunction (107). TGM2 is implicated in Huntington's disease (HD), Parkinson's and Alzheimers' disease. Although intracellular TGase activity is tightly regulated, it is possible that, TGase becomes activated by repeated responses from intracellular injuries, including oxidative stress mediated by mis-folded proteins such as expanded polyQ proteins which results in small transient rises of Ca2+ concentration (108). This allows for the gradual accumulation of TGase-mediated cross-linked products over a long time period which would provide further neurotoxic crosslinked products. This finding may further explain why these diseases manifest so late in life.

Since tTGH, tTGV1 and tTGV2 are not readily inhibited by GTP, they could be readily activated by any transient intracellular Ca+2 spike stimulated by oxidative stress (95) or in diseases associated with mitochondria dysfunction (96, 97). Although tTGV1/2 has less TGase activity, the constitutive crosslinking activity could allow for the gradual accumulation of cross-linked products over a long time period, which could result in further cellular injury. The TGase activity was reported to function as a cofactor to crosslink IkBa and activate NFkB in the nuclei of brain astrocytes and BV-2 microglia (26, 27, 109). As tTGH, tTGV1 and tTGV2 have residual TGase activity, they are postulated to have reduced ability in activating the NFkB inflammatory response and this requires further investigation.

7.3.1. Huntington's disease

In neurodegenerative diseases, TGM2 is known to catalyze the inter- or intra-molecular crosslinking of tau protein, α-synuclein (SYN), and huntingtin forming soluble oligomers, while unmodified or polyaminated disease proteins produced insoluble inclusions (39-41). In vivo data have validated TGM2 as a target for inhibition in HD. Data from cross-breeding TGM2 knock-out (TGM2 KO) (TGM2 -/-) and two different models of HD (R6/1 and R6/2) mice (see below)(110, 111) and pharmacological (cystamine) inhibition (112, 113) all show beneficial effect of inhibiting TGM2's function. Because soluble crosslinked complexes are transient species and not readily detected in vivo, they have been ignored in the past. However, there is recognition that soluble and diffusible high molecular weight oligomeric complexes (or micro-aggregates) are the neurotoxic intermediates in neurodegenerative disorders (114, 115), while the insoluble inclusions could represent a non-toxic pool of insoluble proteins. Moreover, isopeptide bonds are protease-resistant, cannot be easily degraded by the intracellular degradation pathway, may cause proteasome malfunction and trigger neuronal cell death (116).

7.3.2. Parkinson's disease (PD)

The role of TGM2 in Parkinson's disease (PD) was based on several findings including: 1) the discovery of synuclein (SYN) protein as an in vitro and in vivo TGM2 substrate (117, 118); and 2) the increased levels of TGM2-catalyzed cross-links co-localized with SYN in Lewy bodies, which correlated with the development of PD in patients (118). TGM2 interacts directly with SYN both in vitro and in cell models (117, 119). Andringa et al. demonstrated that SYN is indeed a substrate for TGM2 in vivo (118). Increased levels of TGM2-induced intra- and intermolecular cross-linked SYN are observed in PD brains, which suggest that this cross-link precedes further aggregation of SYN into Lewy bodies (118). In addition, crosslinked products of ubiquitin, hsp27, and SYN were also reported in Alzheimer's brains (120). As the crosslinked products contain protease resistant isopeptide bonds, they were postulated to interfere with ubiquitin-proteasome degradation pathway of unfolded proteins (120). These studies suggest that inhibiting the TGM2's cross-linking might prevent the development of Lewy bodies, and thus the development of PD.

7.3.3. Alzheimers' disease (AD)

AD is characterized by the formation of extracellular neurotoxic aggregates consisting of amyloid-beta protein, or intracellular neurotoxic aggregates consisting of hyperphosphorylated tau (121). Both amyloid-beta and tau have been shown as good in vitro substrates of TGM2 (121). Phosphorylated tau accumulated in neurofibrillary tangles, as well as non-phosphorylated tau are substrates for TGM2 (121). In addition, TGase's crosslinking of angiotensin II AT2 receptor causing dysfunctional G-protein signaling was shown to enhance the development of neurodegenerative symptoms in transgenic animal model of Alzheimers' disease (122).

tTGH was shown to be up-regulated in Alzheimer's disease (AD) brains. However, it is not established which brain cells produced this protein and to what extent this form was derived from leukocyte infiltration can not be determined. Quite interestingly, tTGH was shown to be predominantly induced in TNFa and Doxorubicin-induced in NIH3H3 cells (84). This could be due to cellular factor(s) that favor the production of tTGH mRNA and/or the stability of tTGH. In contrast to the role of TGM2 in protecting cell death, increased apoptotic cells were found in NIH3H3 and SKBR3 breast cancer cells transfected with plasmid DNAs encoding tTGH (84). The pro-apoptotic effects were not dependent on its TGase activity because mutants with active site Cys277 mutated did not produce the same effects, nor was it due to GTP binding because tTGH has little or no GTP binding ability (84). It was the tendency of tTGH itself to form aggregated oligomer that triggers the cell death (84). Based on these data, one would expect over-expression of tTGH to increase cell death of brain cells and the possibility of developing Alzheimers' disease. However, this hypothesis remains to be tested.

7.4. Inflammatory diseases

Increased TGase activity is a common feature of several inflammatory diseases. TGM2 is involved in enhanced inflammation by participating in an inflammatory loop with the "master switch" for inflammation, NFkB, and functions by reducing free I-KBa, leading to the translocation of free NFkB into the nucleus (26, 27, 103). In addition to NFkB, several inflammatory cytokines including TNFa, IFN-g (67) and TGF-b1 (68) are known to up-regulate TGM2. In addition, through intramolecular crosslinking and polyamine incorporation, TGM2 can modify PLCA2 (sPLA2), an enzyme that releases arachadonic acid from cell membrane glycerophospholipids, leading to the synthesis of inflammatory eicosanoids. Both modifications significantly augmented the activity of sPLA2 (123-125). Since all spliced forms have reduced TGase activity, abnormal expression of these isoforms will have decrease ability in activating NFkappaB mediated inflammatory pathway.

7.5. Wound healing and fibrosis

TGM2 can be viewed as a micromolecular suturing enzyme (biological glue) that enables tissues to resist proteolytic degradation and acquire enhanced mechanical strength (126). A stable ECM constitutes an important element to promote normal angiogenesis and wound healing (30). TGM2 is secreted by cells and is bound to fibronectin (FN) in the ECM (127). In addition to FN, many ECM proteins including collagen, fibrinogen, fibrin, laminin/nidogen, osteopontin and vitronectin are also substrates of TGM2 (128).

TGM2 expression and activity were increased very early during wound healing, which demonstrate that the TGM2 was activated in cells that were migrating into the fibrin clot and/or remodeling the ECM (72). TGM2 expression occurred in association with TGF-b, TNF-a, IL-6, and VEGF production in the wound (72). How and when TGM2/TGase becomes activated outside the cells and what role it plays in cell biology remains poorly understood. TGM2 can also influence ECM biology by localizing cytokines and protease inhibitors (ECM stabilization phase) to the matrix (129-131). TGM2 can crosslink elafin (a potent inhibitor for elastase) and alpha2-antiplasmin (a potent plasmin inhibitor) to ECM molecules (130, 132, 133). TGM2 binds to beta-1 and beta-3 integrins (53, 61, 134-136) and functions as a co-receptor to promote cell adhesion (136). Moreover, TGM2 is involved in the conversion of latent to active TGFb (137, 138). Active TGFb can also induce TGM2 gene expression leading to further TGF activation which ultimately leads to accumulation of a protease resistant ECM (139, 140).

Under pathological conditions, TGM2 exerts its effects at different phases of wound healing, leading to fibrosis. In the initial phase (trigger/inflammation), TGM2 gene expression is induced by inflammatory cytokines (IL-1, IL-6, TNF-alpha and TGFb (137, 141-144) as a response by damaged tissues to attract inflammatory cells (137). TGM2 can also serve as a receptor to recruit T cells into tissues which would further amplify injury responses (145). It is also possible that tissue injuries produce excessive TGFb resulting in TGM2 up-regulation and extensive ECM crosslinking which leads to a microenviroment in tissues that promotes fibrosis.

These spliced isoforms will have reduced ability in crosslinking ECM substrates as they have reduced TGase activity, which may have effects in slowing down the wound healing process. However, this hypothesis remains to be tested.

7.6. Cell adhesion

TGM2 also functions as an adhesion molecule that contributes to cell-cell and cell-ECM interactions (2). The folding of the N-terminal b-sandwich and two C-terminal b-barrel domains of TGM2 is similar to the immunoglobulin like (IgF)-folding domain, a major family of adhesive proteins that are predicted to be involved in protein-protein interaction (146, 147). Several adhesive proteins including FN, ICAM, VCAM and cadherin (148), all have a similar IgF fold (149). TGM2 binds to FN (2:1 ratio), a glycoprotein present in plasma and the ECM (59), with high affinity (Kd ~8 nM) (60) through its N-terminal b-sandwich domain that aids in the non-classical secretion and localizes TGM2 on the EC surface (14, 54, 150). The catalytic domain of TGM2 helps stabilize the TGM2-FN interaction (54). Through binding to FN, TGM2 also interacts with b1 and b3 integrins which forms stable ternary complexes (14). In fibroblast and monocytic cells, TGM2 also interacts directly with b1 and b3 integrins and associates with the cell surface (14, 15). All spliced forms retain N-terminal b-sandwich domain and are expected to contribute to adhesive function, as TGM2. The role of different spliced isoforms of TGM2 remains to be investigated in this process.

In summary, alternative splicing is an important mechanism for modulating gene function that accounts for a considerable proportion of proteomic complexity in higher eukaryotes. Alternative splicing is often tightly regulated in a cell-type- or developmental-stage- specific manner and can change how a single gene has multiple functions. These C-terminal truncated forms of TGM2 could play an important role in the pathogenesis of various diseases. All these isoforms lack the NES signal sequences, thus they could be localized in nucleus (as demonstrated for tTGv1 and tTGv2) to perform abnormal function. As they are no longer regulated by intracellular GTP, they could be easily activated by the repeated rise in Ca+2 seen in neurodegenerative (or other) diseases; which could contribute to the cross-linking of disease-causing proteins.


This research was funded in part by NIH grants HL072184 (CSG) and NS050541 (TSL). The critical reading of the manuscript by Joseph Meserve is highly appreciated.


1. Folk, J. E. Mechanism and basis for specificity of transglutaminase-catalyzed epsilon-(gamma-glutamyl) lysine bond formation. Adv Enzymol Relat Areas Mol Biol 54, 1-56 (1983)

2. Lorand, L., and Graham, R. M. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 4, 140-156 (2003)

3. Greenberg, C. S., Birckbichler, P. J., and Rice, R. H. Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues. Faseb J 5, 3071-3077. (1991)

4. Nakaoka, H., Perez, D. M., Baek, K. J., Das, T., Husain, A., Misono, K., Im, M. J., and Graham, R. M. Gh: a GTP-binding protein with transglutaminase activity and receptor signaling function. Science 264, 1593-1596 (1994)

5. Im, M. J., Russell, M. A., and Feng, J. F. Transglutaminase II: a new class of GTP-binding protein with new biological functions. Cell Signal 9, 477-482 (1997)

6. Mishra, S., and Murphy, L. J. Tissue transglutaminase has intrinsic kinase activity: identification of transglutaminase 2 as an insulin-like growth factor-binding protein-3 kinase. J Biol Chem 279, 23863-23868 (2004)

7. Mishra, S., Saleh, A., Espino, P. S., Davie, J. R., and Murphy, L. J. Phosphorylation of histones by tissue transglutaminase. J Biol Chem. 281, 5532-8 (2006)

8. Mishra, S., and Murphy, L. J. (2006) The p53 oncoprotein is a substrate for tissue transglutaminase kinase activity. Biochem Biophys Res Commun 339, 726-730

9. Kiraly, R., Demeny, M., and Fesus, L. Protein transamidation by transglutaminase 2 in cells: a disputed Ca2+-dependent action of a multifunctional protein. FEBS J 278, 4717-4739 (2011 Epub)

10. Lai, T. S., Slaughter, T. F., Peoples, K. A., Hettasch, J. M., and Greenberg, C. S. Regulation of human tissue transglutaminase function by magnesium- nucleotide complexes. Identification of distinct binding sites for Mg- GTP and Mg-ATP. J Biol Chem 273, 1776-1781. (1998)

11. Fraij, B. M. GTP hydrolysis by human tissue transglutaminase homologue. Biochem Biophys Res Commun 218, 45-49 (1996)

12. Lai, T. S., Slaughter, T. F., Koropchak, C. M., Haroon, Z. A., and Greenberg, C. S. C-terminal deletion of human tissue transglutaminase enhances magnesium-dependent GTP/ATPase activity. J Biol Chem 271, 31191-31195 (1996)

13. Iismaa, S. E., Chung, L., Wu, M. J., Teller, D. C., Yee, V. C., and Graham, R. M. The core domain of the tissue transglutaminase Gh hydrolyzes GTP and ATP. Biochemistry 36, 11655-11664 (1997)

14. Akimov, S. S., Krylov, D., Fleischman, L. F., and Belkin, A. M. Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin. J Cell Biol 148, 825-838. (2000)

15. Belkin, A. M., Tsurupa, G., Zemskov, E., Veklich, Y., Weisel, J. W., and Medved, L. Transglutaminase-mediated oligomerization of the fibrin(ogen) alphaC domains promotes integrin-dependent cell adhesion and signaling. Blood 105, 3561-3568 (2005)

16. Janiak, A., Zemskov, E. A., and Belkin, A. M. Cell surface transglutaminase promotes RhoA activation via integrin clustering and suppression of the Src-p190RhoGAP signaling pathway. Mol Biol Cell 17, 1606-1619 (2006)

17. Hasegawa, G., Suwa, M., Ichikawa, Y., Ohtsuka, T., Kumagai, S., Kikuchi, M., Sato, Y., and Saito, Y. A novel function of tissue-type transglutaminase: protein disulphide isomerase. Biochem J 373, 793-803 (2003)

18. Antonyak, M. A., Miller, A. M., Jansen, J. M., Boehm, J. E., Balkman, C. E., Wakshlag, J. J., Page, R. L., and Cerione, R. A. Augmentation of tissue transglutaminase expression and activation by epidermal growth factor inhibit doxorubicin-induced apoptosis in human breast cancer cells. J Biol Chem 279, 41461-41467 (2004)

19. Kumar, A., Xu, J., Brady, S., Gao, H., Yu, D., Reuben, J., and Mehta, K. Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells. PLoS One 5, e13390 (2010)

20. Kumar, A., Xu, J., Sung, B., Kumar, S., Yu, D., Aggarwal, B. B., and Mehta, K. Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells. Breast Cancer Res 14, R4 (2012)

21. Li, B., Antonyak, M. A., Druso, J. E., Cheng, L., Nikitin, A. Y., and Cerione, R. A. EGF potentiated oncogenesis requires a tissue transglutaminase-dependent signaling pathway leading to Src activation. Proc Natl Acad Sci U S A 107, 1408-1413 (2010)

22. Kumar, A., Gao, H., Xu, J., Reuben, J., Yu, D., and Mehta, K. Evidence that aberrant expression of tissue transglutaminase promotes stem cell characteristics in mammary epithelial cells. PLoS One 6, e20701 (2011)

23. Cooper, A. J., Wang, J., Pasternack, R., Fuchsbauer, H. L., Sheu, R. K., and Blass, J. P. Lysine-rich histone (H1) is a lysyl substrate of tissue transglutaminase: possible involvement of transglutaminase in the formation of nuclear aggregates in (CAG)(n)/Q(n) expansion diseases. Dev Neurosci 22, 404-417 (2000)

24. Cooper, A. J., Jeitner, T. M., Gentile, V., and Blass, J. P. Cross linking of polyglutamine domains catalyzed by tissue transglutaminase is greatly favored with pathological-length repeats: does transglutaminase activity play a role in (CAG)(n)/Q(n)-expansion diseases? Neurochem Int 40, 53-67. (2002)

25. Cooper, A. J., Sheu, K. R., Burke, J. R., Onodera, O., Strittmatter, W. J., Roses, A. D., and Blass, J. P. Transglutaminase-catalyzed inactivation of glyceraldehyde 3-phosphate dehydrogenase and alpha-ketoglutarate dehydrogenase complex by polyglutamine domains of pathological length. Proc Natl Acad Sci U S A 94, 12604-12609 (1997)

26. Lee, J., Kim, Y. S., Choi, D. H., Bang, M. S., Han, T. R., Joh, T. H., and Kim, S. Y. Transglutaminase 2 induces nuclear factor-kappaB activation via a novel pathway in BV-2 microglia. J Biol Chem 279, 53725-53735 (2004)

27. Mann, A. P., Verma, A., Sethi, G., Manavathi, B., Wang, H., Fok, J. Y., Kunnumakkara, A. B., Kumar, R., Aggarwal, B. B., and Mehta, K. Overexpression of Tissue Transglutaminase Leads to Constitutive Activation of Nuclear Factor-{kappa}B in Cancer Cells: Delineation of a Novel Pathway. Cancer Res 66, 8788-8795 (2006)

28. Karpuj, M. V., Garren, H., Slunt, H., Price, D. L., Gusella, J., Becher, M. W., and Steinman, L. Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei. Proc Natl Acad Sci U S A 96, 7388-7393 (1999)

29. Aeschlimann, D., Mosher, D., and Paulsson, M. Tissue transglutaminase and factor XIII in cartilage and bone remodeling. Semin Thromb Hemost 22, 437-443 (1996)

30. Aeschlimann, D., and Thomazy, V. Protein crosslinking in assembly and remodelling of extracellular matrices: the role of transglutaminases. Connect Tissue Res 41, 1-27 (2000)

31. Boros, S., Ahrman, E., Wunderink, L., Kamps, B., de Jong, W. W., Boelens, W. C., and Emanuelsson, C. S. Site-specific transamidation and deamidation of the small heat-shock protein Hsp20 by tissue transglutaminase. Proteins 62, 1044-1052 (2006)

32. Achyuthan, K. E., and Greenberg, C. S. Identification of a guanosine triphosphate-binding site on guinea pig liver transglutaminase. Role of GTP and calcium ions in modulating activity. J Biol Chem 262, 1901-1906 (1987)

33. Stamnaes, J., Pinkas, D. M., Fleckenstein, B., Khosla, C., and Sollid, L. M. Redox regulation of transglutaminase 2 activity. J Biol Chem 285, 25402-25409 (2010)

34. Jin, X., Stamnaes, J., Klock, C., DiRaimondo, T. R., Sollid, L. M., and Khosla, C. Activation of extracellular transglutaminase 2 by thioredoxin. J Biol Chem 286, 37866-37873 (2011)

35. Santhanam, L., Tuday, E. C., Webb, A. K., Dowzicky, P., Kim, J. H., Oh, Y. J., Sikka, G., Kuo, M., Halushka, M. K., Macgregor, A. M., Dunn, J., Gutbrod, S., Yin, D., Shoukas, A., Nyhan, D., Flavahan, N. A., Belkin, A. M., and Berkowitz, D. E. Decreased S-nitrosylation of tissue transglutaminase contributes to age-related increases in vascular stiffness. Circ Res 107, 117-125 (2010)

36. Lai, T. S., Hausladen, A., Slaughter, T. F., Eu, J. P., Stamler, J. S., and Greenberg, C. S. Calcium regulates S-nitrosylation, denitrosylation, and activity of tissue transglutaminase. Biochemistry 40, 4904-4910 (2001)

37. Kim, S. Y. Transglutaminase 2 in inflammation. Front Biosci 11, 3026-3035 (2006)

38. Szondy, Z., Sarang, Z., Molnar, P., Nemeth, T., Piacentini, M., Mastroberardino, P. G., Falasca, L., Aeschlimann, D., Kovacs, J., Kiss, I., Szegezdi, E., Lakos, G., Rajnavolgyi, E., Birckbichler, P. J., Melino, G., and Fesus, L. Transglutaminase 2-/- mice reveal a phagocytosis-associated crosstalk between macrophages and apoptotic cells. Proc Natl Acad Sci U S A 100, 7812-7817 (2003)

39. Konno, T., Morii, T., Shimizu, H., Oiki, S., and Ikura, K. Paradoxical inhibition of protein aggregation and precipitation by transglutaminase-catalyzed intermolecular cross-linking. J Biol Chem 280, 17520-17525 (2005)

40. Lai, T., Tucker, T., Burke, JR., Strittmatter, WJ., and Greenberg, CS Effect of Tissue Transglutaminase on the Solubility of Proteins Containing Expanded Polyglutamine Repeats. J. Neurochemistry 88, 1253-1260 (2004)

41. Konno, T., Morii, T., Hirata, A., Sato, S., Oiki, S., and Ikura, K. Covalent blocking of fibril formation and aggregation of intracellular amyloidgenic proteins by transglutaminase-catalyzed intramolecular cross-linking. Biochemistry 44, 2072-2079 (2005)

42. Murthy, S. N., Lomasney, J. W., Mak, E. C., and Lorand, L. Interactions of G(h)/transglutaminase with phospholipase Cdelta1 and with GTP. Proc Natl Acad Sci U S A 96, 11815-11819 (1999)

43. Liu, S., Cerione, R. A., and Clardy, J. Structural basis for the guanine nucleotide-binding activity of tissue transglutaminase and its regulation of transamidation activity. Proc Natl Acad Sci U S A 99, 2743-2747 (2002)

44. Pinkas, D. M., Strop, P., Brunger, A. T., and Khosla, C. Transglutaminase 2 undergoes a large conformational change upon activation. PLoS Biol 5, e327 (2007)

45. Mishra, S., and Murphy, L. J. Phosphorylation of transglutaminase 2 by PKA at Ser216 creates 14-3-3 binding sites. Biochem Biophys Res Commun 347, 1166-1170 (2006)

46. Mishra, S., Melino, G., and Murphy, L. J. Transglutaminase 2 kinase activity facilitates protein kinase A-induced phosphorylation of retinoblastoma protein. J Biol Chem 282, 18108-18115 (2007)

47. Mackintosh, C. Dynamic interactions between 14-3-3 proteins and phosphoproteins regulate diverse cellular processes. Biochem J 381, 329-342 (2004)

48. Bae, J., Lee, Y. S., and Jeoung, D. Down-regulation of transglutaminase II leads to impaired motility of cancer cells by inactivation of the protein kinase, Akt, and decrease of reactive oxygen species. Biotechnol Lett 28, 1151-1158 (2006)

49. Han, B. G., Cho, J. W., Cho, Y. D., Jeong, K. C., Kim, S. Y., and Lee, B. I. Crystal structure of human transglutaminase 2 in complex with adenosine triphosphate. Int J Biol Macromol 47, 190-195 (2010)

50. Begg, G. E., Holman, S. R., Stokes, P. H., Matthews, J. M., Graham, R. M., and Iismaa, S. E. Mutation of a critical arginine in the GTP-binding site of transglutaminase 2 disinhibits intracellular cross-linking activity. J Biol Chem 281, 12603-12609 (2006)

51. Lai, T. S., Liu, Y., Li, W., and Greenberg, C. S. Identification of two GTP-independent alternatively spliced forms of tissue transglutaminase in human leukocytes, vascular smooth muscle, and endothelial cells. FASEB J 21, 4131-4143 (2007)

52. Lesort, M., Attanavanich, K., Zhang, J., and Johnson, G. V. Distinct nuclear localization and activity of tissue transglutaminase. J Biol Chem 273, 11991-11994 (1998)

53. Akimov, S. S., and Belkin, A. M. Cell surface tissue transglutaminase is involved in adhesion and migration of monocytic cells on fibronectin. Blood 98, 1567-1576 (2001)

54. Hang, J., Zemskov, E. A., Lorand, L., and Belkin, A. M. Identification of a novel recognition sequence for fibronectin within the NH2-terminal beta-sandwich domain of tissue transglutaminase. J Biol Chem 280, 23675-23683 (2005)

55. Xu, L., Begum, S., Hearn, J. D., and Hynes, R. O. GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2, and inhibits melanoma tumor growth and metastasis. Proc Natl Acad Sci U S A 103, 9023-9028 (2006)

56. Nemes, Z., Jr., Adany, R., Balazs, M., Boross, P., and Fesus, L. Identification of cytoplasmic actin as an abundant glutaminyl substrate for tissue transglutaminase in HL-60 and U937 cells undergoing apoptosis. J Biol Chem 272, 20577-20583 (1997)

57. Peng, X., Zhang, Y., Zhang, H., Graner, S., Williams, J. F., Levitt, M. L., and Lokshin, A. Interaction of tissue transglutaminase with nuclear transport protein importin-alpha3. FEBS Lett 446, 35-39 (1999)

58. Singh, U. S., Li, Q., and Cerione, R. Identification of the eukaryotic initiation factor 5A as a retinoic acid-stimulated cellular binding partner for tissue transglutaminase II. J Biol Chem 273, 1946-1950 (1998)

59. Hynes, R. O. The dynamic dialogue between cells and matrices: implications of fibronectin's elasticity. Proc Natl Acad Sci U S A 96, 2588-2590 (1999)

60. Turner, P. M., and Lorand, L. Complexation of fibronectin with tissue transglutaminase. Biochemistry 28, 628-635 (1989)

61. Akimov, S. S., and Belkin, A. M. Cell-surface transglutaminase promotes fibronectin assembly via interaction with the gelatin-binding domain of fibronectin: a role in TGFbeta-dependent matrix deposition. J Cell Sci 114, 2989-3000 (2001)

62. Zemskov, E. A., Mikhailenko, I., Hsia, R. C., Zaritskaya, L., and Belkin, A. M. Unconventional secretion of tissue transglutaminase involves phospholipid-dependent delivery into recycling endosomes. PLoS One 6, e19414 (2011 Epub)

63. Scarpellini, A., Germack, R., Lortat-Jacob, H., Muramatsu, T., Billett, E., Johnson, T., and Verderio, E. A. Heparan sulfate proteoglycans are receptors for the cell-surface trafficking and biological activity of transglutaminase-2. J Biol Chem 284, 18411-18423 (2009)

64. Wang, Z., Collighan, R. J., Pytel, K., Rathbone, D. L., Li, X., and Griffin, M. Characterization of Heparin-binding Site of Tissue Transglutaminase: ITS IMPORTANCE IN CELL SURFACE TARGETING, MATRIX DEPOSITION, AND CELL SIGNALING. J Biol Chem 287, 13063-13083 (2012)

65. Antonyak, M. A., Li, B., Boroughs, L. K., Johnson, J. L., Druso, J. E., Bryant, K. L., Holowka, D. A., and Cerione, R. A. Cancer cell-derived microvesicles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells. Proc Natl Acad Sci U S A 108, 4852-4857 (2011)

66. Mirza, A., Liu, S. L., Frizell, E., Zhu, J., Maddukuri, S., Martinez, J., Davies, P., Schwarting, R., Norton, P., and Zern, M. A. A role for tissue transglutaminase in hepatic injury and fibrogenesis, and its regulation by NF-kappaB. Am J Physiol 272, G281-288 (1997)

67. Kim, S. Y., Jeong, E. J., and Steinert, P. M. IFN-gamma induces transglutaminase 2 expression in rat small intestinal cells. J Interferon Cytokine Res 22, 677-682 (2002)

68. Quan, G., Choi, J. Y., Lee, D. S., and Lee, S. C. TGF-beta1 up-regulates transglutaminase two and fibronectin in dermal fibroblasts: a possible mechanism for the stabilization of tissue inflammation. Arch Dermatol Res 297, 84-90 (2005)

69. Shull, M. M., Ormsby, I., Kier, A. B., Pawlowski, S., Diebold, R. J., Yin, M., Allen, R., Sidman, C., Proetzel, G., Calvin, D., and et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359, 693-699 (1992)

70. Bergamini, C. M., Griffin, M., and Pansini, F. S. Transglutaminase and vascular biology: physiopathologic implications and perspectives for therapeutic interventions. Curr Med Chem 12, 2357-2372 (2005)

71. Balajthy, Z., Csomos, K., Vamosi, G., Szanto, A., Lanotte, M., and Fesus, L. Tissue-transglutaminase contributes to neutrophil granulocyte differentiation and functions. Blood 108, 2045-2054 (2006)

72. Haroon, Z. A., Hettasch, J. M., Lai, T. S., Dewhirst, M. W., and Greenberg, C. S. Tissue transglutaminase is expressed, active, and directly involved in rat dermal wound healing and angiogenesis. Faseb J 13, 1787-1795 (1999)

73. Haroon, Z. A., Lai, T. S., Hettasch, J. M., Lindberg, R. A., Dewhirst, M. W., and Greenberg, C. S. Tissue transglutaminase is expressed as a host response to tumor invasion and inhibits tumor growth. Lab Invest 79, 1679-1686 (1999)

74. Haroon, Z. A., Wannenburg, T., Gupta, M., Greenberg, C. S., Wallin, R., and Sane, D. C. Localization of tissue transglutaminase in human carotid and coronary artery atherosclerosis: implications for plaque stability and progression. Lab Invest 81, 83-93 (2001)

75. Fraij, B. M., Birckbichler, P. J., Patterson, M. K., Jr., Lee, K. N., and Gonzales, R. A. A retinoic acid-inducible mRNA from human erythroleukemia cells encodes a novel tissue transglutaminase homologue. J Biol Chem 267, 22616-22623 (1992)

76. Fraij, B. M., and Gonzales, R. A. A third human tissue transglutaminase homologue as a result of alternative gene transcripts. Biochim Biophys Acta 1306, 63-74 (1996)

77. Fraij, B. M., and Gonzales, R. A. Organization and structure of the human tissue transglutaminase gene. Biochim Biophys Acta 1354, 65-71 (1997)

78. Iismaa, S. E., Begg, G. E., and Graham, R. M. Cross-linking transglutaminases with G protein-coupled receptor signaling. Sci STKE 2006, pe34 (2006)

79. Kojima, S., Kuo, T. F., and Tatsukawa, H. Regulation of transglutaminase-mediated hepatic cell death in alcoholic steatohepatitis and non-alcoholic steatohepatitis. J Gastroenterol Hepatol 27 Suppl 2, 52-57 (2012)

80. Lortat-Jacob, H., Burhan, I., Scarpellini, A., Thomas, A., Imberty, A., Vives, R. R., Johnson, T., Gutierrez, A., and Verderio, E. A. Transglutaminase-2 interaction with heparin: identification of a heparin binding site that regulates cell adhesion to fibronectin-transglutaminase-2 matrix. J Biol Chem (2012 Epub)

81. Ast, G. How did alternative splicing evolve? Nat Rev Genet 5, 773-782 (2004)

82. Citron, B. A., SantaCruz, K. S., Davies, P. J., and Festoff, B. W. Intron-exon swapping of transglutaminase mRNA and neuronal Tau aggregation in Alzheimer's disease. J Biol Chem 276, 3295-3301 (2001)

83. Citron, B. A., Suo, Z., SantaCruz, K., Davies, P. J., Qin, F., and Festoff, B. W. Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration. Neurochem Int 40, 69-78. (2002)

84. Antonyak, M. A., Jansen, J. M., Miller, A. M., Ly, T. K., Endo, M., and Cerione, R. A. Two isoforms of tissue transglutaminase mediate opposing cellular fates. Proc Natl Acad Sci U S A, 103, 18609-18614 (2006)

85. Antonyak, M. A., Singh, U. S., Lee, D. A., Boehm, J. E., Combs, C., Zgola, M. M., Page, R. L., and Cerione, R. A. Effects of tissue transglutaminase on retinoic acid-induced cellular differentiation and protection against apoptosis. J Biol Chem 276, 33582-33587 (2001)

86. Jeon, J. H., Cho, S. Y., Kim, C. W., Shin, D. M., Kweon, J. C., Choi, K. H., Park, S. C., and Kim, I. G. GTP is required to stabilize and display transamidation activity of transglutaminase 2. Biochem Biophys Res Commun 294, 818-822 (2002)

87. Begg, G. E., Holman, S. R., Stokes, P. H., Matthews, J. M., Graham, R. M., and Iismaa, S. E. Mutation of a critical GTP-binding arginine in transglutaminase 2 disinhibits intracellular crosslinking activity. J Biol Chem 281, 12603-9 (2006)

88. Monsonego, A., Shani, Y., Friedmann, I., Paas, Y., Eizenberg, O., and Schwartz, M. Expression of GTP-dependent and GTP-independent tissue-type transglutaminase in cytokine-treated rat brain astrocytes. J Biol Chem 272, 3724-3732 (1997)

89. Monsonego, A., Friedmann, I., Shani, Y., Eisenstein, M., and Schwartz, M. GTP-dependent conformational changes associated with the functional switch between Galpha and cross-linking activities in brain-derived tissue transglutaminase. J Mol Biol 282, 713-720 (1998)

90. Festoff, B. W., SantaCruz, K., Arnold, P. M., Sebastian, C. T., Davies, P. J., and Citron, B. A. Injury-induced "switch" from GTP-regulated to novel GTP-independent isoform of tissue transglutaminase in the rat spinal cord. J Neurochem 81, 708-718 (2002)

91. Tolentino, P. J., Waghray, A., Wang, K. K., and Hayes, R. L. Increased expression of tissue-type transglutaminase following middle cerebral artery occlusion in rats. J Neurochem 89, 1301-1307 (2004)

92. Tolentino, P. J., DeFord, S. M., Notterpek, L., Glenn, C. C., Pike, B. R., Wang, K. K., and Hayes, R. L. Up-regulation of tissue-type transglutaminase after traumatic brain injury. J Neurochem 80, 579-588 (2002)

93. Yamaga, M., Fujii, M., Kamata, H., Hirata, H., and Yagisawa, H. Phospholipase C-delta1 contains a functional nuclear export signal sequence. J Biol Chem 274, 28537-28541 (1999)

94. Irvine, R. F. 20 years of Ins(1,4,5)P3, and 40 years before. Nat Rev Mol Cell Biol 4, 586-590 (2003)

95. Shin, D. M., Jeon, J. H., Kim, C. W., Cho, S. Y., Kwon, J. C., Lee, H. J., Choi, K. H., Park, S. C., and Kim, I. G. Cell type-specific activation of intracellular transglutaminase 2 by oxidative stress or ultraviolet irradiation: implications of transglutaminase 2 in age-related cataractogenesis. J Biol Chem 279, 15032-15039 (2004)

96. Fox, J. H., Barber, D. S., Singh, B., Zucker, B., Swindell, M. K., Norflus, F., Buzescu, R., Chopra, R., Ferrante, R. J., Kazantsev, A., and Hersch, S. M. Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation. J Neurochem 91, 413-422 (2004)

97. Minghetti, L. Role of inflammation in neurodegenerative diseases. Curr Opin Neurol 18, 315-321 (2005)

98. Tee, A. E., Marshall, G. M., Liu, P. Y., Xu, N., Haber, M., Norris, M. D., Iismaa, S. E., and Liu, T. Opposing effects of two tissue transglutaminase protein isoforms in neuroblastoma cell differentiation. J Biol Chem 285, 3561-3567 (2009)

99. Phatak, V. M., Croft, S. M., Rameshaiah Setty, S. G., Scarpellini, A., Hughes, D. C., Rees, R., McArdle, S., and Verderio, E. A. Expression of transglutaminase-2 isoforms in normal human tissues and cancer cell lines: dysregulation of alternative splicing in cancer. Amino Acids (2011 Epub)

100. David, C. J., and Manley, J. L. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev 24, 2343-2364 (2010)

101. Thiery, J. P. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2, 442-454 (2002)

102. Nunes, I., Gleizes, P. E., Metz, C. N., and Rifkin, D. B. Latent transforming growth factor-beta binding protein domains involved in activation and transglutaminase-dependent cross-linking of latent transforming growth factor-beta. J Cell Biol 136, 1151-1163 (1997)

103. Verma, A., and Mehta, K. Transglutaminase-Mediated Activation of Nuclear Transcription Factor-kappaB in Cancer Cells: A New Therapeutic Opportunity. Curr Cancer Drug Targets 7, 559-565 (2007)

104. Lin, C. Y., Tsai, P. H., Kandaswami, C. C., Chang, G. D., Cheng, C. H., Huang, C. J., Lee, P. P., Hwang, J. J., and Lee, M. T. Role of tissue transglutaminase 2 in the acquisition of the mesenchymal-like phenotype in highly invasive A431 tumor cells. Mol Cancer 10, 87 (2011)

105. Huynh, M. L., Fadok, V. A., and Henson, P. M. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J Clin Invest 109, 41-50 (2002)

106. Falasca, L., Iadevaia, V., Ciccosanti, F., Melino, G., Serafino, A., and Piacentini, M. Transglutaminase type II is a key element in the regulation of the anti-inflammatory response elicited by apoptotic cell engulfment. J Immunol 174, 7330-7340 (2005)

107. Jeitner, T. M., Muma, N. A., Battaile, K. P., and Cooper, A. J. Transglutaminase activation in neurodegenerative diseases. Future Neurol 4, 449-467 (2009)

108. Panov, A. V., Gutekunst, C. A., Leavitt, B. R., Hayden, M. R., Burke, J. R., Strittmatter, W. J., and Greenamyre, J. T. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 5, 731-736 (2002)

109. Caccamo, D., Campisi, A., Curro, M., Aguennouz, M., Li Volti, G., Avola, R., and Ientile, R. Nuclear factor-kappab activation is associated with glutamate-evoked tissue transglutaminase up-regulation in primary astrocyte cultures. J Neurosci Res 82, 858-865 (2005)

110. Mastroberardino, P. G., Iannicola, C., Nardacci, R., Bernassola, F., De Laurenzi, V., Melino, G., Moreno, S., Pavone, F., Oliverio, S., Fesus, L., and Piacentini, M. 'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease. Cell Death Differ 9, 873-880. (2002)

111. Bailey, C. D., and Johnson, G. V. Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms. J Neurochem 92, 83-92 (2005)

112. Karpuj, M. V., Becher, M. W., Springer, J. E., Chabas, D., Youssef, S., Pedotti, R., Mitchell, D., and Steinman, L. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 8, 143-149. (2002)

113. Dedeoglu, A., Kubilus, J. K., Jeitner, T. M., Matson, S. A., Bogdanov, M., Kowall, N. W., Matson, W. R., Cooper, A. J., Ratan, R. R., Beal, M. F., Hersch, S. M., and Ferrante, R. J. Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci 22, 8942-8950. (2002)

114. Orr, H. T. Neurodegenerative disease: neuron protection agency. Nature 431, 747-748 (2004)

115. Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R., and Finkbeiner, S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805-810 (2004)

116. Mandrusiak, L. M., Beitel, L. K., Wang, X., Scanlon, T. C., Chevalier-Larsen, E., Merry, D. E., and Trifiro, M. A. Transglutaminase potentiates ligand-dependent proteasome dysfunction induced by polyglutamine-expanded androgen receptor. Hum Mol Genet 12, 1497-1506 (2003)

117. Junn, E., Ronchetti, R. D., Quezado, M. M., Kim, S. Y., and Mouradian, M. M. Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A 100, 2047-2052. (2003)

118. Andringa, G., Lam, K. Y., Chegary, M., Wang, X., Chase, T. N., and Bennett, M. C. Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease. FASEB J 18, 932-934 (2004)

119. Jensen, P. H., Sorensen, E. S., Petersen, T. E., Gliemann, J., and Rasmussen, L. K. Residues in the synuclein consensus motif of the alpha-synuclein fragment, NAC, participate in transglutaminase-catalysed cross-linking to Alzheimer-disease amyloid beta A4 peptide. Biochem J 310 (Pt 1), 91-94 (1995)

120. Nemes, Z., Devreese, B., Steinert, P. M., Van Beeumen, J., and Fesus, L. Cross-linking of ubiquitin, HSP27, parkin, and alpha-synuclein by gamma-glutamyl-epsilon-lysine bonds in Alzheimer's neurofibrillary tangles. FASEB J 18, 1135-1137 (2004)

121. Wilhelmus, M. M., van Dam, A. M., and Drukarch, B. Tissue transglutaminase: a novel pharmacological target in preventing toxic protein aggregation in neurodegenerative diseases. Eur J Pharmacol 585, 464-472 (2008)

122. AbdAlla, S., Lother, H., el Missiry, A., Langer, A., Sergeev, P., el Faramawy, Y., and Quitterer, U. Angiotensin II AT2 receptor oligomers mediate G-protein dysfunction in an animal model of Alzheimer disease. J Biol Chem 284, 6554-6565 (2009)

123. Cordella-Miele, E., Miele, L., Beninati, S., and Mukherjee, A. B. Stimulation of phospholipases A2 by transglutaminases. Adv Exp Med Biol 279, 105-123 (1990)

124. Cordella-Miele, E., Miele, L., and Mukherjee, A. B. A novel transglutaminase-mediated post-translational modification of phospholipase A2 dramatically increases its catalytic activity. J Biol Chem 265, 17180-17188 (1990)

125. Miele, L. New weapons against inflammation: dual inhibitors of phospholipase A2 and transglutaminase. J Clin Invest 111, 19-21 (2003)

126. Griffin, M., Casadio, R., and Bergamini, C. M. Transglutaminases: nature's biological glues. Biochem J 368, 377-396 (2002)

127. Balklava, Z., Verderio, E., Collighan, R., Gross, S., Adams, J., and Griffin, M. Analysis of tissue transglutaminase function in the migration of Swiss 3T3 fibroblasts: the active-state conformation of the enzyme does not affect cell motility but is important for its secretion. J Biol Chem 277, 16567-16575 (2002)

128. Esposito, C., and Caputo, I. Mammalian transglutaminases. Identification of substrates as a key to physiological function and physiopathological relevance. Febs J 272, 615-631 (2005)

129. Larreta-Garde, V., and Berry, H. Modeling extracellular matrix degradation balance with proteinase/transglutaminase cycle. J Theor Biol 217, 105-124 (2002)

130. Nakane, H., Ishida-Yamamoto, A., Takahashi, H., and Iizuka, H. Elafin, a secretory protein, is cross-linked into the cornified cell envelopes from the inside of psoriatic keratinocytes. J Invest Dermatol 119, 50-55 (2002)

131. Verderio, E. A., Johnson, T., and Griffin, M. Tissue transglutaminase in normal and abnormal wound healing: review article. Amino Acids 26, 387-404 (2004)

132. Ritchie, H., Lawrie, L. C., Mosesson, M. W., and Booth, N. A. Characterization of crosslinking sites in fibrinogen for plasminogen activator inhibitor 2 (PAI-2). Ann N Y Acad Sci 936, 215-218 (2001)

133. Lee, K. N., Lee, C. S., Tae, W. C., Jackson, K. W., Christiansen, V. J., and McKee, P. A. Cross-linking of wild-type and mutant alpha 2-antiplasmins to fibrin by activated factor XIII and by a tissue transglutaminase. J Biol Chem 275, 37382-37389 (2000)

134. Agah, A., Kyriakides, T. R., and Bornstein, P. Proteolysis of cell-surface tissue transglutaminase by matrix metalloproteinase-2 contributes to the adhesive defect and matrix abnormalities in thrombospondin-2-null fibroblasts and mice. Am J Pathol 167, 81-88 (2005)

135. Verderio, E. A., Telci, D., Okoye, A., Melino, G., and Griffin, M. A novel RGD-independent cel adhesion pathway mediated by fibronectin-bound tissue transglutaminase rescues cells from anoikis. J Biol Chem 278, 42604-42614 (2003)

136. Akimov, S. S., Krylov, D., Fleischman, L. F., and Belkin, A. M. Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin. J Cell Biol 148, 825-838 (2000)

137. Le, M., Gohr, C. M., and Rosenthal, A. K. Transglutaminase participates in the incorporation of latent TGFbeta into the extracellular matrix of aging articular chondrocytes. Connect Tissue Res 42, 245-253 (2001)

138. Yang, L., Tredget, E. E., and Ghahary, A. Activation of latent transforming growth factor-beta1 is induced by mannose 6-phosphate/insulin-like growth factor-II receptor. Wound Repair Regen 8, 538-546 (2000)

139. George, M. D., Vollberg, T. M., Floyd, E. E., Stein, J. P., and Jetten, A. M. Regulation of transglutaminase type II by transforming growth factor-beta 1 in normal and transformed human epidermal keratinocytes. J Biol Chem 265, 11098-11104 (1990)

140. Haroon, Z. A., Amin, K., Saito, W., Wilson, W., Greenberg, C. S., and Dewhirst, M. W. SU5416 delays wound healing through inhibition of TGF-beta 1 activation. Cancer Biol Ther 1, 121-126 (2002)

141. Nieder, C., Zimmermann, F. B., Adam, M., and Molls, M. The role of pentoxifylline as a modifier of radiation therapy. Cancer Treat Rev 31, 448-455 (2005)

142. Suto, N., Ikura, K., and Sasaki, R. Expression induced by interleukin-6 of tissue-type transglutaminase in human hepatoblastoma HepG2 cells. J Biol Chem 268, 7469-7473 (1993)

143. Johnson, T. S., El-Koraie, A. F., Skill, N. J., Baddour, N. M., El Nahas, A. M., Njloma, M., Adam, A. G., and Griffin, M. Tissue transglutaminase and the progression of human renal scarring. J Am Soc Nephrol 14, 2052-2062 (2003)

144. Skill, N. J., Johnson, T. S., Coutts, I. G., Saint, R. E., Fisher, M., Huang, L., El Nahas, A. M., Collighan, R. J., and Griffin, M. Inhibition of transglutaminase activity reduces extracellular matrix accumulation induced by high glucose levels in proximal tubular epithelial cells. J Biol Chem 279, 47754-47762 (2004)

145. Mohan, K., Pinto, D., and Issekutz, T. B. Identification of tissue transglutaminase as a novel molecule involved in human CD8+ T cell transendothelial migration. J Immunol 171, 3179-3186 (2003)

146. Bork, P., Holm, L., and Sander, C. The immunoglobulin fold. Structural classification, sequence patterns and common core. J Mol Biol 242, 309-320 (1994)

147. Murzin, A. G., Brenner, S. E., Hubbard, T., and Chothia, C. SCOP: a structural classification of proteins database for the investigation of sequences and structures. J Mol Biol 247, 536-540 (1995)

148. Simon, S. I., and Green, C. E. Molecular mechanics and dynamics of leukocyte recruitment during inflammation. Annu Rev Biomed Eng 7, 151-185 (2005)

149. Ichikawa, S., Hatanaka, H., Yuuki, T., Iwamoto, N., Kojima, S., Nishiyama, C., Ogura, K., Okumura, Y., and Inagaki, F. Solution structure of Der f 2, the major mite allergen for atopic diseases. J Biol Chem 273, 356-360 (1998)

150. Gaudry, C. A., Verderio, E., Aeschlimann, D., Cox, A., Smith, C., and Griffin, M. Cell surface localization of tissue transglutaminase is dependent on a fibronectin-binding site in its N-terminal beta-sandwich domain. J Biol Chem 274, 30707-30714 (1999)

Key Words: Alternative Splicing, Transglutaminase, Cancer, Neurodegenerative, Wound Healing, Review

Send correspondence to: Charles S Greenberg, Medical University of South Carolina, 96 Jonathan Lucas Street, Charleston, SC 29425, Tel: 843-792 9300, Fax: 843-792-0644, E-mail: greenbec@musc.edu